Bioventus (BVS) Net Cash Flow (2020 - 2026)

Bioventus' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$14.8 million for Q1 2026.

• Quarterly Net Cash Flow rose 23.04% year-over-year to -$14.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (up 1846.62% YoY) and the FY2025 annual result came in at $9.3 million, up 29.35% from the prior year.
• Net Cash Flow was -$14.8 million for Q1 2026 at Bioventus, down from $8.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $17.0 million in Q2 2023 and bottomed at -$41.4 million in Q3 2022.
• A 5-year average of -$3.0 million and a median of -$4.3 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 583.78% — and 2025, when it jumped 1465.85%.
• Bioventus' Net Cash Flow stood at -$4.5 million in 2022, then soared by 319.23% to $9.8 million in 2023, then sank by 94.15% to $571000.0 in 2024, then soared by 1465.85% to $8.9 million in 2025, then plunged by 265.35% to -$14.8 million in 2026.
• Business Quant data shows BVS's Net Cash Flow at -$14.8 million in Q1 2026, $8.9 million in Q4 2025, and $9.6 million in Q3 2025.